Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors.

导出 OA

翻译打印收藏纠错

第一作者： Masafumi,Ikeda

第一单位： Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

作者： Masafumi,Ikeda ^[1] ; Susumu,Hijioka ^[2] ; Tetsuhide,Ito ^[3] ; Shigemi,Matsumoto ^[4] ; Yoshitaka,Honma ^[5] ; Makoto,Ueno ^[6] ; Naohiro,Okano ^[7] ; Taku,Aoki ^[8] ; Junji,Furuse ^[6]

作者单位： Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. ^[1] Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[2] Department of Gastroenterology and Hepatology, International University of Health and Welfare Graduate School of Medicine, Neuroendocrine Tumor Center, Fukuoka Sanno Hospital, Fukuoka, Japan. ^[3] Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan. ^[4] Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[5] Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. ^[6] Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan. ^[7] Department of Hepato-Biliary-Pancreatic Surgery, Dokkyo Medical University, Tochigi, Japan. ^[8]

关键词 cytotoxic agent molecular-targeted agent pancreatic neuroendocrine tumor somatostatin analog treatment selection MAP